22-May-2026
Tandem Diabetes Shareholders Approve Governance and Incentive Changes
TipRanks (Thu, 21-May 4:51 PM ET)
Market Chameleon (Fri, 8-May 4:49 AM ET)
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
Business Wire (Thu, 7-May 4:05 PM ET)
Tandem Diabetes Care Announces Upcoming Conference Presentations
Business Wire (Wed, 29-Apr 4:05 PM ET)
Business Wire (Mon, 27-Apr 9:00 AM ET)
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Business Wire (Thu, 2-Apr 4:05 PM ET)
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
Globe Newswire (Fri, 27-Mar 9:00 AM ET)
Tandem Mobi Now Compatible with Android Smartphones
Business Wire (Wed, 4-Mar 5:00 PM ET)
Tandem Diabetes Care Sets New Sales Records and Expands Margins Amid Business Model Transformation
Market Chameleon (Fri, 20-Feb 5:32 AM ET)
Record Sales and Expanding Margins Highlight TNDM’s Third Quarter—Profitability Still in Focus
Market Chameleon (Fri, 7-Nov 6:59 AM ET)
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Tandem Diabetes Care trades on the NASDAQ stock market under the symbol TNDM.
As of May 22, 2026, TNDM stock price declined to $14.97 with 1,829,348 million shares trading.
TNDM has a beta of -0.58, meaning it tends to be less sensitive to market movements. TNDM has a correlation of 0.01 to the broad based SPY ETF.
TNDM has a market cap of $1.03 billion. This is considered a Small Cap stock.
Last quarter Tandem Diabetes Care reported $247 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.15.
In the last 3 years, TNDM traded as high as $53.69 and as low as $9.98.
The top ETF exchange traded funds that TNDM belongs to (by Net Assets): IJR, VTI, VB, IWM, VBK.
TNDM has underperformed the market in the last year with a price return of -27.5% while the SPY ETF gained +29.1%. TNDM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.1% and -3.3%, respectively, while the SPY returned +8.4% and +1.1%, respectively.
TNDM support price is $14.97 and resistance is $16.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNDM shares will trade within this expected range on the day.